{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "8996058e-0cc0-4c83-b473-edf8264a8352",
   "metadata": {},
   "source": [
    "# **Overview of the EHR Retrieval System**\n",
    "\n",
    "This code demonstrates the process of **retrieving relevant treatment records** from a dataset of patient medical records, based on a set of user-defined queries. It uses **semantic search** techniques to match the query with relevant records, allowing for more flexible and meaningful comparisons rather than relying on exact text matching. Here’s how the system works:\n",
    "\n",
    "### **1. Loading Multiple Datasets**\n",
    "The code begins by processing multiple **JSON dataset files** (`1.json`, `2.json`, `3.json`), each representing a collection of medical records. The datasets contain patient treatment history, which is used for further analysis.\n",
    "\n",
    "### **2. Preprocessing the Data**\n",
    "For each dataset:\n",
    "- The data is **cleaned** using the `_clean_text` method, which removes sensitive information like patient names or IDs.\n",
    "- The text is then **split into sections** based on common section headers like “Plan”, “Treatment”, and “Assessment”.\n",
    "- Relevant sections are identified based on the presence of **radiation treatment terms** (e.g., \"radiation\", \"chemotherapy\", \"EBRT\").\n",
    "- The method checks if the treatments are from the **past**, by comparing treatment dates with a **hardcoded current date**.\n",
    "\n",
    "### **3. Defining Queries**\n",
    "The system works with predefined **queries** related to cancer treatments and follow-up care. These queries include questions like:\n",
    "- \"Was chemotherapy administered?\"\n",
    "- \"Did the patient undergo surgery?\"\n",
    "- \"What follow-up imaging or lab tests were planned?\"\n",
    "\n",
    "These queries are intended to extract information from the preprocessed treatment records.\n",
    "\n",
    "### **4. Retrieving Relevant Treatment Records**\n",
    "For each query:\n",
    "- The **treatment records** are encoded using a **SentenceTransformer model**, which converts both the query and treatment records into **vector representations**.\n",
    "- **Cosine similarity** is then calculated between the query and the treatment records to measure how similar each record is to the query.\n",
    "- The top `N` most relevant records are selected based on their similarity scores.\n",
    "\n",
    "### **5. Displaying Results**\n",
    "The system retrieves and **displays the top matching treatment records** for each query, sorted by their relevance. For each result, it shows:\n",
    "- The treatment record and its similarity score.\n",
    "- The results are sorted in descending order of relevance, with the most relevant treatments displayed first.\n",
    "\n",
    "### **Why This Approach?**\n",
    "This method allows for **semantic matching** of patient records with queries, ensuring that the system finds the most relevant treatment records even if the phrasing differs. It’s particularly useful in healthcare settings where medical terms and treatments are varied, and the system needs to understand the meaning rather than relying on exact keyword matches.\n",
    "\n",
    "### **Summary**\n",
    "This code processes and searches medical records based on specific treatment-related queries, allowing healthcare professionals to quickly retrieve the most relevant patient information. It utilizes natural language processing and machine learning to **automatically identify** treatments, assess their relevance, and display the results, all while respecting patient privacy by cleaning sensitive data.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "155b2781-5765-4160-9753-c578db4c7468",
   "metadata": {},
   "source": [
    "## Core Dependencies\n",
    "- **json**: Handles reading/writing of JSON-formatted EHR data\n",
    "- **re**: Performs regex pattern matching for text cleaning\n",
    "- **numpy**: Enables numerical operations for similarity scoring\n",
    "- **datetime**: Manages temporal filtering of medical records\n",
    "- **SentenceTransformer**: Powers semantic text embeddings (using 'paraphrase-MiniLM-L6-v2' model)\n",
    "- **cosine_similarity**: Computes similarity between query and document embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "63b417be-9587-4ffc-8d53-72dd954307a9",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import re\n",
    "import numpy as np\n",
    "from datetime import datetime\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from sklearn.metrics.pairwise import cosine_similarity"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e5213b10-8179-43cf-82a3-d085832c6924",
   "metadata": {},
   "source": [
    "## EHR Retrieval System Setup\n",
    "- **patient_data**: Stores loaded JSON medical records\n",
    "- **model**: Initializes lightweight sentence embedding model (80MB)\n",
    "- **chunks**: Holds preprocessed text segments\n",
    "- **current_date**: Simulated future date (2026-01-01) for testing temporal filters\n",
    "- **Purpose**: Creates framework for handling oncology EHR data analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "fedf2481-9fc3-44a0-b225-58e78aa61f29",
   "metadata": {},
   "outputs": [],
   "source": [
    "class EHRRetrievalSystem:\n",
    "    def __init__(self, patient_data):\n",
    "        self.patient_data = patient_data  # Store patient data passed during initialization\n",
    "        self.model = SentenceTransformer('paraphrase-MiniLM-L6-v2')  # Load the pre-trained SentenceTransformer model for sentence embeddings\n",
    "        self.chunks = []  # Initialize an empty list to store the processed chunks of relevant treatment information\n",
    "        # Simulate current date as 2026 for testing\n",
    "        self.current_date = datetime(2026, 1, 1)  # Use a future date for testing purposes (hardcoded date for date comparison)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1354a893-2817-4332-9426-8e9ab51f060a",
   "metadata": {},
   "source": [
    "## Protected Health Information (PHI) Redaction\n",
    "- Removes sensitive patient identifiers using regex patterns:\n",
    "  - Patient Name\n",
    "  - Medical Record Number (MRN)\n",
    "  - Location data\n",
    "- Preserves clinical content while maintaining HIPAA compliance\n",
    "- Operates case-insensitively to catch variations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "7cd1c0c0-88f2-4511-ba73-d53c6474dc25",
   "metadata": {},
   "outputs": [],
   "source": [
    "def _clean_text(self, text):\n",
    "    \"\"\"Lightweight PHI removal\"\"\"\n",
    "    # Remove sensitive patient information like name, MRN, and location from the text\n",
    "    return re.sub(r'(Patient Name|MRN|Location):.*?\\n', '', text, flags=re.IGNORECASE)\n",
    "\n",
    "EHRRetrievalSystem._clean_text = _clean_text  # Attach the _clean_text method to the EHRRetrievalSystem class\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cfe72ebe-d740-4011-b01c-79a85502361b",
   "metadata": {},
   "source": [
    "## Date Validation System\n",
    "- Handles multiple date formats (MM-DD-YYYY and MM/DD/YYYY)\n",
    "- Converts string dates to datetime objects for comparison\n",
    "- Returns True if treatment occurred before simulated current date (2026)\n",
    "- Error-tolerant design skips malformed dates"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "9842ea26-82e4-431b-9e26-ef61ab618904",
   "metadata": {},
   "outputs": [],
   "source": [
    "def _is_past_treatment(self, chunk_text):\n",
    "    \"\"\"Robust date parsing for MM-DD-YYYY and MM/DD/YYYY\"\"\"\n",
    "    date_formats = [r'\\d{2}-\\d{2}-\\d{4}', r'\\d{2}/\\d{2}/\\d{4}']  # Define date formats for both MM-DD-YYYY and MM/DD/YYYY\n",
    "    for fmt in date_formats:\n",
    "        match = re.search(fmt, chunk_text)  # Search for a date match in the chunk text\n",
    "        if match:\n",
    "            date_str = match.group()  # Extract the matched date string\n",
    "            try:\n",
    "                # Parse the date string to a datetime object based on the format\n",
    "                date_obj = datetime.strptime(date_str, '%m-%d-%Y' if '-' in date_str else '%m/%d/%Y')\n",
    "                # Check if the parsed date is earlier than the current date\n",
    "                return date_obj.date() < self.current_date.date()\n",
    "            except:\n",
    "                continue  # In case of error, skip to next format\n",
    "    return False  # Return False if no valid past date is found\n",
    "\n",
    "EHRRetrievalSystem._is_past_treatment = _is_past_treatment  # Attach the _is_past_treatment method to the EHRRetrievalSystem class\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "35837b3f-2a66-4fc6-bf61-3334e174bc99",
   "metadata": {},
   "source": [
    "## Radiation Therapy Identifier\n",
    "- Regex pattern matches radiation-specific terms:\n",
    "  - Radiation/radiotherapy\n",
    "  - Brachytherapy/EBRT/XRT\n",
    "  - Advanced techniques (proton therapy, stereotactic)\n",
    "- Case-insensitive search (re.I flag)\n",
    "- Covers both technical and colloquial treatment names"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "48714d6e-f642-4ec2-bc62-cd77b1665401",
   "metadata": {},
   "outputs": [],
   "source": [
    "def _contains_treatment(self, text):\n",
    "    \"\"\"Check for radiation-related treatments\"\"\"\n",
    "    # Use regex to search for radiation-related terms in the provided text (case-insensitive)\n",
    "    return re.search(\n",
    "        r'\\b(radiation|radiotherapy|brachytherapy|EBRT|XRT|external beam|seed implant|proton therapy|stereotactic)\\b', \n",
    "        text, re.I  # 're.I' makes the search case-insensitive\n",
    "    )\n",
    "\n",
    "EHRRetrievalSystem._contains_treatment = _contains_treatment  # Attach the _contains_treatment method to the EHRRetrievalSystem class\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "47ff4e54-7a29-4139-94dd-38f5a21932f6",
   "metadata": {},
   "source": [
    "## Clinical Text Processing Pipeline\n",
    "1. Cleans PHI from raw EHR text\n",
    "2. Splits documents into clinical sections using headers:\n",
    "   - Plan\n",
    "   - Treatment\n",
    "   - Imaging Findings\n",
    "   - Assessment\n",
    "   - Conclusion\n",
    "3. Combines header + content for context preservation\n",
    "4. Filters sections containing radiation treatments\n",
    "5. Validates treatment dates against temporal constraints"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "8b1114a4-3aca-4721-b983-ed477f6b110b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def preprocess(self):\n",
    "    \"\"\"Extract and preprocess relevant treatment data\"\"\"\n",
    "    for doc in self.patient_data:\n",
    "        cleaned = self._clean_text(doc['docText'])  # Clean text to remove sensitive information\n",
    "        date_str = doc['docDate'].replace('-', '/')  # Replace dashes with slashes in the date string for consistency\n",
    "        \n",
    "        # Split the cleaned text into sections based on common headers like 'Plan:', 'Treatment:', etc.\n",
    "        sections = re.split(r'\\n\\s*(Plan:|Treatment:|Imaging Findings:|Assessment:|Conclusion:)', cleaned)\n",
    "        \n",
    "        # Iterate through the sections to find treatment-related content\n",
    "        for i in range(1, len(sections), 2):\n",
    "            section = sections[i] + sections[i+1]  # Combine the section header with the content\n",
    "            if self._contains_treatment(section) and len(section) > 30:  # Check if treatment-related info is found and the section is long enough\n",
    "                chunk = f\"{doc['docTitle']} ({date_str}): {section.strip()}\"  # Format the chunk with document title and date\n",
    "                if self._is_past_treatment(chunk):  # Check if the treatment date is in the past\n",
    "                    self.chunks.append(chunk)  # Add the relevant chunk to the list of chunks\n",
    "\n",
    "EHRRetrievalSystem.preprocess = preprocess  # Attach the preprocess method to the EHRRetrievalSystem class"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "00d52db7-914d-4de5-b506-8a0063a018f7",
   "metadata": {},
   "source": [
    "## Neural Information Retrieval\n",
    "1. Encodes text chunks into 384-dim vectors\n",
    "2. Computes query embedding using same model\n",
    "3. Calculates cosine similarity scores\n",
    "4. Selects top 3 most relevant matches\n",
    "5. Returns results with confidence scores (0-1 scale)\n",
    "- Uses batch processing for memory efficiency"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "efe7ee3e-4c23-4e14-a14c-0bc02b83c607",
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve(self, query, top_n=3):\n",
    "    \"\"\"Retrieve most relevant treatment records\"\"\"\n",
    "    if not self.chunks:\n",
    "        return []  # If no chunks are available, return an empty list\n",
    "    \n",
    "    # Encode the chunks (treatment records) and the query into embeddings (numerical representations)\n",
    "    chunk_embs = self.model.encode(self.chunks, batch_size=16, convert_to_numpy=True)  # Encode all treatment chunks\n",
    "    query_emb = self.model.encode(query)  # Encode the query into an embedding\n",
    "    \n",
    "    # Compute cosine similarity between the query embedding and the chunk embeddings\n",
    "    scores = cosine_similarity([query_emb], chunk_embs)[0]  # Calculate similarity scores for each chunk\n",
    "    \n",
    "    # Find the indices of the top_n most similar chunks\n",
    "    top_indices = np.argpartition(scores, -top_n)[-top_n:]  # Get the indices of the top_n relevant chunks\n",
    "    \n",
    "    # Return the top_n most relevant treatment records along with their similarity scores\n",
    "    return [(self.chunks[i], scores[i]) for i in top_indices]\n",
    "\n",
    "EHRRetrievalSystem.retrieve = retrieve  # Attach the retrieve method to the EHRRetrievalSystem class\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7e9f5136-02c8-4c7b-a56b-45a9f239a31f",
   "metadata": {},
   "source": [
    "## Multi-Dataset Analysis Process\n",
    "- Processes 3 cancer datasets sequentially:\n",
    "  1. Breast cancer (1.json)\n",
    "  2. Lung cancer (2.json)\n",
    "  3. Prostate cancer (3.json)\n",
    "  \n",
    "- Runs 5 clinical queries per dataset:\n",
    "  1. Treatment options by stage\n",
    "  2. Chemotherapy administration\n",
    "  3. Recurrence monitoring\n",
    "  4. Surgical history\n",
    "  5. Specific AC chemo verification\n",
    "  \n",
    "- Outputs ranked results with similarity scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "a0433793-c61d-44e8-86b9-13e09700fe7d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Processing Dataset: 1.json\n",
      "--------------------------------------------------\n",
      "\n",
      "Query 1: What were the recommended treatment options based on the patient’s cancer stage and pathology?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.58] Medical Oncology Consultation – Adjuvant Therapy Planning (02/26/2020): Assessment:\n",
      "Given her receptor profile, she is a candidate for combined chemotherapy and HER2-targeted therapy (e.g., trastuzumab). She also qualifies for hormonal therapy (an aromatase inhibitor or tamoxifen) after the completion of chemotherapy, due to her ER/PR positivity.\n",
      "\n",
      "Proposed Treatment Plan:\n",
      "1. **Chemotherapy Regimen**: A regimen such as doxorubicin and cyclophosphamide (AC) for 4 cycles, followed by paclitaxel (T) weekly for 12 weeks, is a standard approach. \n",
      "2. **HER2-Targeted Therapy**: Trastuzumab (and possibly pertuzumab) can be started concurrently with the taxane portion of chemotherapy and continued for a total of 12 months (adjuvant setting). Cardiac function monitoring (echocardiogram or MUGA scan) is required, as HER2-targeted agents can impact ejection fraction.\n",
      "3. **Hormonal Therapy**: Given her ER/PR positivity, she will likely start an aromatase inhibitor (like letrozole) post-chemotherapy if she is confirmed to be fully menopausal. If not, tamoxifen could be used. Duration typically is 5–10 years.\n",
      "4. **Radiation Therapy**: Will be coordinated with radiation oncology. Usually starts after completing AC portion of chemotherapy but can vary depending on institutional protocols.\n",
      "\n",
      "Patient Education:\n",
      "Mrs. Bowman was informed of the potential side effects of the proposed regimen, which can include:\n",
      "- Nausea, vomiting, mucositis from AC.\n",
      "- Hair loss associated with both AC and paclitaxel.\n",
      "- Neuropathy, especially with paclitaxel.\n",
      "- Cardiotoxicity risk with doxorubicin and HER2-targeted drugs (hence the need for baseline and follow-up echocardiograms).\n",
      "- Fatigue, myelosuppression, and increased infection risk.\n",
      "\n",
      "Discussion:\n",
      "We discussed the importance of adhering to the chemotherapy schedule and the potential for dose adjustments if severe toxicities occur. We will also consider growth factor support if neutropenia becomes dose-limiting. The patient expressed understanding and readiness to proceed, acknowledging that the next few months of therapy will be challenging.\n",
      "\n",
      "2. [0.58] Mid-Radiation Therapy Follow-up (10/20/2020): Plan:\n",
      "- Complete the remaining 15 radiation treatments, aiming for a total dose of ~50.4 Gy.\n",
      "- Evaluate the need for a tumor bed boost based on the final lumpectomy bed location and margin status, although some centers do a standard boost after whole breast radiation.\n",
      "- Follow up weekly to monitor skin integrity and overall tolerance.\n",
      "\n",
      "3. [0.56] Postoperative Follow-up – Surgical Oncology Visit (02/20/2020): Plan:\n",
      "1. **Referral to Medical Oncology**: Mrs. Bowman will meet with Dr. Robert Chan, medical oncologist, to discuss adjuvant chemotherapy combined with HER2-targeted treatment (e.g., trastuzumab). \n",
      "2. **Radiation Oncology Consultation**: Since she opted for lumpectomy, postoperative radiation therapy is standard to reduce local recurrence risk.\n",
      "3. **Physical Therapy**: If arm stiffness and range-of-motion issues persist, she may benefit from physical therapy or a lymphedema prevention program.\n",
      "4. **Incision Care**: Continue to keep incisions clean and dry, watch for signs of infection. Sutures are absorbable, so no suture removal is required. She can resume gentle activities but should avoid heavy lifting (>10 lbs) for at least two more weeks.\n",
      "\n",
      "Patient Education:\n",
      "Mrs. Bowman was reminded to maintain a healthy diet and stay hydrated as she approaches further treatment. She was advised on the importance of adhering to her follow-up schedule, which includes medical oncology, radiation oncology, and routine breast imaging.\n",
      "\n",
      "Follow-up:\n",
      "- Appointment with medical oncology is scheduled for 02/26/2020.\n",
      "- Return to surgical oncology in approximately 3–4 weeks, unless complications arise.\n",
      "\n",
      "\n",
      "Query 2: Was chemotherapy administered?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.53] Chemotherapy Cycle 3 – Doxorubicin and Cyclophosphamide (04/21/2020): Conclusion:\n",
      "Mrs. Bowman’s treatment course remains on track. Side effects are tolerable but accumulating. She continues to express a positive outlook and has supportive family members accompanying her to appointments. Coordination with radiation oncology will be arranged after AC completion, and then the transition to paclitaxel plus trastuzumab will be planned.\n",
      "\n",
      "2. [0.51] Medical Oncology Consultation – Adjuvant Therapy Planning (02/26/2020): Assessment:\n",
      "Given her receptor profile, she is a candidate for combined chemotherapy and HER2-targeted therapy (e.g., trastuzumab). She also qualifies for hormonal therapy (an aromatase inhibitor or tamoxifen) after the completion of chemotherapy, due to her ER/PR positivity.\n",
      "\n",
      "Proposed Treatment Plan:\n",
      "1. **Chemotherapy Regimen**: A regimen such as doxorubicin and cyclophosphamide (AC) for 4 cycles, followed by paclitaxel (T) weekly for 12 weeks, is a standard approach. \n",
      "2. **HER2-Targeted Therapy**: Trastuzumab (and possibly pertuzumab) can be started concurrently with the taxane portion of chemotherapy and continued for a total of 12 months (adjuvant setting). Cardiac function monitoring (echocardiogram or MUGA scan) is required, as HER2-targeted agents can impact ejection fraction.\n",
      "3. **Hormonal Therapy**: Given her ER/PR positivity, she will likely start an aromatase inhibitor (like letrozole) post-chemotherapy if she is confirmed to be fully menopausal. If not, tamoxifen could be used. Duration typically is 5–10 years.\n",
      "4. **Radiation Therapy**: Will be coordinated with radiation oncology. Usually starts after completing AC portion of chemotherapy but can vary depending on institutional protocols.\n",
      "\n",
      "Patient Education:\n",
      "Mrs. Bowman was informed of the potential side effects of the proposed regimen, which can include:\n",
      "- Nausea, vomiting, mucositis from AC.\n",
      "- Hair loss associated with both AC and paclitaxel.\n",
      "- Neuropathy, especially with paclitaxel.\n",
      "- Cardiotoxicity risk with doxorubicin and HER2-targeted drugs (hence the need for baseline and follow-up echocardiograms).\n",
      "- Fatigue, myelosuppression, and increased infection risk.\n",
      "\n",
      "Discussion:\n",
      "We discussed the importance of adhering to the chemotherapy schedule and the potential for dose adjustments if severe toxicities occur. We will also consider growth factor support if neutropenia becomes dose-limiting. The patient expressed understanding and readiness to proceed, acknowledging that the next few months of therapy will be challenging.\n",
      "\n",
      "3. [0.49] Chemotherapy Cycle 4 – Doxorubicin and Cyclophosphamide Completion (05/12/2020): Plan:\n",
      "- Mrs. Bowman will have a 2–3 week break before transitioning to paclitaxel + trastuzumab.\n",
      "- She will meet again with Dr. Chan to finalize the schedule and assess if any supportive medications (e.g., growth factors) are needed.\n",
      "- Radiation oncology consult will be arranged, but typically full-course radiation may be deferred until after the completion of paclitaxel, or may begin concurrently, depending on the institutional protocol.\n",
      "\n",
      "\n",
      "Query 3: What follow-up imaging or lab tests were planned to monitor for recurrence?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.43] Postoperative Follow-up – Surgical Oncology Visit (02/20/2020): Conclusion:\n",
      "The patient is recovering well post-surgery. She is informed of the next steps for systemic and radiation therapy to optimize her long-term outcomes.\n",
      "\n",
      "2. [0.42] Mid-Radiation Therapy Follow-up (10/20/2020): Conclusion:\n",
      "Mrs. Bowman’s radiation course is proceeding as planned. Mild skin changes are within expected parameters. She remains compliant with daily treatments and has good support at home. The team will reassess her condition and skin reaction in another week.\n",
      "\n",
      "3. [0.41] Operative Report – Lumpectomy and Sentinel Lymph Node Biopsy (02/10/2020): Plan:\n",
      "- Await final pathology results for margin status and lymph node involvement.\n",
      "- Follow-up appointment in one week for incision check and pathology review.\n",
      "- Possible referral to medical oncology for systemic therapy decision and radiation oncology for adjuvant radiation planning.\n",
      "\n",
      "Operative Notes:\n",
      "Mrs. Bowman was informed preoperatively about the risks of bleeding, infection, and the possibility of re-excision if margins were positive. Initial frozen section results were reassuring, but permanent section pathology remains definitive. She will be educated on wound care, signs of infection, and advised to limit strenuous activity for 2–3 weeks.\n",
      "\n",
      "\n",
      "Query 4: Did the patient undergo surgery?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.49] Operative Report – Lumpectomy and Sentinel Lymph Node Biopsy (02/10/2020): Plan:\n",
      "- Await final pathology results for margin status and lymph node involvement.\n",
      "- Follow-up appointment in one week for incision check and pathology review.\n",
      "- Possible referral to medical oncology for systemic therapy decision and radiation oncology for adjuvant radiation planning.\n",
      "\n",
      "Operative Notes:\n",
      "Mrs. Bowman was informed preoperatively about the risks of bleeding, infection, and the possibility of re-excision if margins were positive. Initial frozen section results were reassuring, but permanent section pathology remains definitive. She will be educated on wound care, signs of infection, and advised to limit strenuous activity for 2–3 weeks.\n",
      "\n",
      "2. [0.47] Postoperative Follow-up – Surgical Oncology Visit (02/20/2020): Conclusion:\n",
      "The patient is recovering well post-surgery. She is informed of the next steps for systemic and radiation therapy to optimize her long-term outcomes.\n",
      "\n",
      "3. [0.45] Surgical Oncology Consultation – Treatment Plan Discussion (01/25/2020): Plan:\n",
      "- Schedule outpatient lumpectomy and sentinel lymph node biopsy within the next two weeks.\n",
      "- Proceed with final staging once pathology from the sentinel node is available.\n",
      "- Consider adjuvant therapy based on stage and receptor status.\n",
      "\n",
      "Patient Education:\n",
      "Mrs. Bowman was given literature on breast-conserving surgery vs. mastectomy, as well as information on postoperative expectations, including possible side effects such as pain, infection, and lymphedema risk. She was encouraged to follow up with her medical oncologist to discuss systemic therapy and with a radiation oncologist to plan for postoperative radiation.\n",
      "\n",
      "\n",
      "Query 5: Has the patient undergone AC chemotherapy?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.55] Medical Oncology Consultation – Adjuvant Therapy Planning (02/26/2020): Plan:\n",
      "- Obtain a baseline echocardiogram prior to initiating therapy.\n",
      "- Schedule AC chemotherapy to begin in approximately 1–2 weeks.\n",
      "- Coordinate with radiation oncology to plan for post-AC radiation.\n",
      "- Re-assess after 4 cycles of AC to transition to paclitaxel plus concurrent trastuzumab.\n",
      "\n",
      "2. [0.53] Postoperative Follow-up – Surgical Oncology Visit (02/20/2020): Conclusion:\n",
      "The patient is recovering well post-surgery. She is informed of the next steps for systemic and radiation therapy to optimize her long-term outcomes.\n",
      "\n",
      "3. [0.50] Chemotherapy Cycle 3 – Doxorubicin and Cyclophosphamide (04/21/2020): Conclusion:\n",
      "Mrs. Bowman’s treatment course remains on track. Side effects are tolerable but accumulating. She continues to express a positive outlook and has supportive family members accompanying her to appointments. Coordination with radiation oncology will be arranged after AC completion, and then the transition to paclitaxel plus trastuzumab will be planned.\n",
      "\n",
      "\n",
      "Processing Dataset: 2.json\n",
      "--------------------------------------------------\n",
      "\n",
      "Query 1: What were the recommended treatment options based on the patient’s cancer stage and pathology?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.63] Oncology Consultation - Treatment Planning (01/03/2020): Plan:\n",
      "- Arrange a cardiothoracic surgery consult within the next week. Evaluate resectability and surgical risk based on imaging and pulmonary function.\n",
      "- Await molecular testing results. \n",
      "- Discuss the possibility of concurrent chemotherapy and radiation therapy if surgery is not an optimal route.\n",
      "\n",
      "2. [0.58] Multidisciplinary Team Meeting - Final Treatment Decision (01/17/2020): Conclusion:\n",
      "The team agreed that curative-intent surgery followed by adjuvant therapy remains the best approach for Mr. Whitfield. He has been counseled on the likely postoperative course, potential complications, and the importance of close follow-up to detect any recurrence. A provisional post-surgery therapy plan includes a standard four-cycle chemotherapy regimen, with radiation therapy contingent on surgical findings. This multidisciplinary consensus will be shared with Mr. Whitfield at his next clinic visit.\n",
      "\n",
      "3. [0.56] Final (4th) Chemotherapy Cycle - Completion and Next Steps (05/12/2020): Plan:\n",
      "- He will see Dr. Olson in two weeks for a post-chemotherapy assessment, lab check, and to discuss long-term surveillance strategies.\n",
      "- Additional supportive care or rehabilitative measures (e.g., physical therapy, nutritional counseling) may be offered if fatigue or neuropathy remains problematic.\n",
      "- Consider a consultation with radiation oncology only if new evidence of locoregional recurrence appears or if guidelines suggest a benefit. Currently, no postoperative radiation is planned due to negative mediastinal nodes and clear resection margins.\n",
      "\n",
      "\n",
      "Query 2: Was chemotherapy administered?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.50] Final (4th) Chemotherapy Cycle - Completion and Next Steps (05/12/2020): Plan:\n",
      "- He will see Dr. Olson in two weeks for a post-chemotherapy assessment, lab check, and to discuss long-term surveillance strategies.\n",
      "- Additional supportive care or rehabilitative measures (e.g., physical therapy, nutritional counseling) may be offered if fatigue or neuropathy remains problematic.\n",
      "- Consider a consultation with radiation oncology only if new evidence of locoregional recurrence appears or if guidelines suggest a benefit. Currently, no postoperative radiation is planned due to negative mediastinal nodes and clear resection margins.\n",
      "\n",
      "2. [0.39] Multidisciplinary Team Meeting - Final Treatment Decision (01/17/2020): Conclusion:\n",
      "The team agreed that curative-intent surgery followed by adjuvant therapy remains the best approach for Mr. Whitfield. He has been counseled on the likely postoperative course, potential complications, and the importance of close follow-up to detect any recurrence. A provisional post-surgery therapy plan includes a standard four-cycle chemotherapy regimen, with radiation therapy contingent on surgical findings. This multidisciplinary consensus will be shared with Mr. Whitfield at his next clinic visit.\n",
      "\n",
      "3. [0.39] Oncology Consultation - Treatment Planning (01/03/2020): Plan:\n",
      "- Arrange a cardiothoracic surgery consult within the next week. Evaluate resectability and surgical risk based on imaging and pulmonary function.\n",
      "- Await molecular testing results. \n",
      "- Discuss the possibility of concurrent chemotherapy and radiation therapy if surgery is not an optimal route.\n",
      "\n",
      "\n",
      "Query 3: What follow-up imaging or lab tests were planned to monitor for recurrence?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.48] Final (4th) Chemotherapy Cycle - Completion and Next Steps (05/12/2020): Plan:\n",
      "- He will see Dr. Olson in two weeks for a post-chemotherapy assessment, lab check, and to discuss long-term surveillance strategies.\n",
      "- Additional supportive care or rehabilitative measures (e.g., physical therapy, nutritional counseling) may be offered if fatigue or neuropathy remains problematic.\n",
      "- Consider a consultation with radiation oncology only if new evidence of locoregional recurrence appears or if guidelines suggest a benefit. Currently, no postoperative radiation is planned due to negative mediastinal nodes and clear resection margins.\n",
      "\n",
      "2. [0.47] Oncology Consultation - Treatment Planning (01/03/2020): Assessment:\n",
      "Based on current imaging and pathology, Mr. Whitfield’s disease appears to be confined to the right upper lobe region with nodal involvement but no detected distant spread. This classification suggests a potentially locally advanced but not metastatic disease, which could be approached with either surgical resection followed by adjuvant therapy, or a definitive chemo-radiation strategy if surgery is not optimal.\n",
      "\n",
      "Treatment Discussion:\n",
      "1. **Surgical Consultation**: Dr. Olson recommended that Mr. Whitfield be evaluated by a thoracic surgeon to consider a lobectomy or pneumonectomy, depending on the location and extent of the tumor. However, the involvement of the hilar lymph node might necessitate careful staging of the mediastinum.\n",
      "2. **Combined Modality Approach**: If the tumor is borderline resectable or if the patient’s pulmonary function tests suggest that extensive resection could compromise quality of life, a combination of chemotherapy and radiation might be the preferred approach.\n",
      "3. **Neoadjuvant vs. Adjuvant Therapy**: In cases where partial tumor shrinkage is desired before surgery, neoadjuvant chemotherapy or chemoradiation could be employed. Adjuvant therapy may be indicated post-surgery to reduce recurrence risk.\n",
      "4. **Targeted or Immunotherapy**: Pending the results of molecular markers and PD-L1 status, targeted therapies (e.g., EGFR inhibitors) or immunotherapy (checkpoint inhibitors) might become a consideration in the adjuvant or palliative setting if the disease changes or if further molecular data warrant it.\n",
      "\n",
      "Patient Preferences:\n",
      "Mr. Whitfield expressed concern about the side effects of chemotherapy and radiation, particularly fatigue and potential lung toxicity. He also mentioned wanting the most definitive approach possible to maximize his chances of a cure or long-term remission. He indicated he is willing to undergo surgery if it is deemed feasible and beneficial.\n",
      "\n",
      "3. [0.47] Multidisciplinary Team Meeting - Final Treatment Decision (01/17/2020): Conclusion:\n",
      "The team agreed that curative-intent surgery followed by adjuvant therapy remains the best approach for Mr. Whitfield. He has been counseled on the likely postoperative course, potential complications, and the importance of close follow-up to detect any recurrence. A provisional post-surgery therapy plan includes a standard four-cycle chemotherapy regimen, with radiation therapy contingent on surgical findings. This multidisciplinary consensus will be shared with Mr. Whitfield at his next clinic visit.\n",
      "\n",
      "\n",
      "Query 4: Did the patient undergo surgery?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.52] Thoracic Surgery Consultation - Resectability Evaluation (01/10/2020): Plan:\n",
      "- Additional imaging or staging procedures may be needed to confirm no mediastinal involvement beyond N1.\n",
      "- Evaluate the potential for resectability. If a right upper lobectomy is deemed feasible, proceed with surgery followed by adjuvant chemotherapy and possibly radiation, depending on final pathology.\n",
      "- If advanced nodal disease or borderline resectability is discovered intraoperatively, the surgeon may consider a more extensive resection or abort surgery in favor of a definitive chemoradiation approach.\n",
      "\n",
      "2. [0.42] Oncology Consultation - Treatment Planning (01/03/2020): Assessment:\n",
      "Based on current imaging and pathology, Mr. Whitfield’s disease appears to be confined to the right upper lobe region with nodal involvement but no detected distant spread. This classification suggests a potentially locally advanced but not metastatic disease, which could be approached with either surgical resection followed by adjuvant therapy, or a definitive chemo-radiation strategy if surgery is not optimal.\n",
      "\n",
      "Treatment Discussion:\n",
      "1. **Surgical Consultation**: Dr. Olson recommended that Mr. Whitfield be evaluated by a thoracic surgeon to consider a lobectomy or pneumonectomy, depending on the location and extent of the tumor. However, the involvement of the hilar lymph node might necessitate careful staging of the mediastinum.\n",
      "2. **Combined Modality Approach**: If the tumor is borderline resectable or if the patient’s pulmonary function tests suggest that extensive resection could compromise quality of life, a combination of chemotherapy and radiation might be the preferred approach.\n",
      "3. **Neoadjuvant vs. Adjuvant Therapy**: In cases where partial tumor shrinkage is desired before surgery, neoadjuvant chemotherapy or chemoradiation could be employed. Adjuvant therapy may be indicated post-surgery to reduce recurrence risk.\n",
      "4. **Targeted or Immunotherapy**: Pending the results of molecular markers and PD-L1 status, targeted therapies (e.g., EGFR inhibitors) or immunotherapy (checkpoint inhibitors) might become a consideration in the adjuvant or palliative setting if the disease changes or if further molecular data warrant it.\n",
      "\n",
      "Patient Preferences:\n",
      "Mr. Whitfield expressed concern about the side effects of chemotherapy and radiation, particularly fatigue and potential lung toxicity. He also mentioned wanting the most definitive approach possible to maximize his chances of a cure or long-term remission. He indicated he is willing to undergo surgery if it is deemed feasible and beneficial.\n",
      "\n",
      "3. [0.41] Oncology Consultation - Treatment Planning (01/03/2020): Plan:\n",
      "- Arrange a cardiothoracic surgery consult within the next week. Evaluate resectability and surgical risk based on imaging and pulmonary function.\n",
      "- Await molecular testing results. \n",
      "- Discuss the possibility of concurrent chemotherapy and radiation therapy if surgery is not an optimal route.\n",
      "\n",
      "\n",
      "Query 5: Has the patient undergone AC chemotherapy?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.49] Final (4th) Chemotherapy Cycle - Completion and Next Steps (05/12/2020): Plan:\n",
      "- He will see Dr. Olson in two weeks for a post-chemotherapy assessment, lab check, and to discuss long-term surveillance strategies.\n",
      "- Additional supportive care or rehabilitative measures (e.g., physical therapy, nutritional counseling) may be offered if fatigue or neuropathy remains problematic.\n",
      "- Consider a consultation with radiation oncology only if new evidence of locoregional recurrence appears or if guidelines suggest a benefit. Currently, no postoperative radiation is planned due to negative mediastinal nodes and clear resection margins.\n",
      "\n",
      "2. [0.47] Oncology Consultation - Treatment Planning (01/03/2020): Plan:\n",
      "- Arrange a cardiothoracic surgery consult within the next week. Evaluate resectability and surgical risk based on imaging and pulmonary function.\n",
      "- Await molecular testing results. \n",
      "- Discuss the possibility of concurrent chemotherapy and radiation therapy if surgery is not an optimal route.\n",
      "\n",
      "3. [0.45] Thoracic Surgery Consultation - Resectability Evaluation (01/10/2020): Plan:\n",
      "- Additional imaging or staging procedures may be needed to confirm no mediastinal involvement beyond N1.\n",
      "- Evaluate the potential for resectability. If a right upper lobectomy is deemed feasible, proceed with surgery followed by adjuvant chemotherapy and possibly radiation, depending on final pathology.\n",
      "- If advanced nodal disease or borderline resectability is discovered intraoperatively, the surgeon may consider a more extensive resection or abort surgery in favor of a definitive chemoradiation approach.\n",
      "\n",
      "\n",
      "Processing Dataset: 3.json\n",
      "--------------------------------------------------\n",
      "\n",
      "Query 1: What were the recommended treatment options based on the patient’s cancer stage and pathology?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.55] Radiation Oncology Consultation (05/02/2025): Plan:\n",
      "- If Mr. Henderson opts for radiation, a CT simulation and MRI fusion would be the next step to precisely map the prostate and adjacent structures.\n",
      "- He is encouraged to weigh the benefits and drawbacks of surgery versus radiation. Both have high cure rates in localized intermediate-risk prostate cancer, though the side effect profiles differ.\n",
      "- Dr. Zhao advises an informed decision after considering quality of life, personal preference, and risk tolerance.\n",
      "\n",
      "2. [0.53] MRI and Bone Scan Results - Staging Evaluation (04/20/2025): Assessment:\n",
      "Based on these imaging findings, Mr. Henderson’s disease is likely clinically staged as T2 N0 M0, which correlates with a stage consistent with organ-confined or at least regionally limited prostate cancer. This staging suggests he is a good candidate for definitive local therapy, such as surgery or radiation.\n",
      "\n",
      "Plan for Treatment:\n",
      "Dr. Turner reaffirms two primary curative approaches:\n",
      "- **Radical Prostatectomy** (Open or Robotic-Assisted): Typically recommended for men with a life expectancy beyond 10 years and localized disease. This could be combined with pelvic lymph node dissection, given his intermediate risk. Potential side effects discussed again include erectile dysfunction, incontinence, and typical surgical risks.\n",
      "- **Radiation Therapy**: External beam radiation therapy over several weeks or brachytherapy. May be combined with short-term androgen deprivation therapy (ADT) if considered necessary for intermediate-risk disease. Side effects can include urinary frequency, dysuria, and bowel-related issues like proctitis.\n",
      "\n",
      "Patient Discussion:\n",
      "Mr. Henderson states that he wants to be aggressive in treating the cancer and is inclined towards surgery. He has concerns about urinary incontinence but acknowledges that modern techniques may help preserve function. Dr. Turner suggests that he also speak with a radiation oncologist to fully understand all options. They review basic guidelines indicating that Gleason 7 disease typically warrants definitive therapy unless significant comorbidities preclude aggressive management.\n",
      "\n",
      "Next Steps:\n",
      "- Refer to a radiation oncology consult if the patient desires a second opinion.\n",
      "- If Mr. Henderson proceeds with surgery, schedule preoperative labs, EKG, and anesthesia consultation.\n",
      "- Begin pelvic floor exercises preoperatively to help with post-surgery continence.\n",
      "\n",
      "3. [0.51] Radiation Oncology Consultation (05/02/2025): Conclusion:\n",
      "Mr. Henderson expresses gratitude for the thorough explanation. He will consult with Dr. Turner (urology) again before making a final choice. He acknowledges that either surgery or radiation can be curative, and his decision will revolve around which side effect profile he finds more acceptable.\n",
      "\n",
      "\n",
      "Query 2: Was chemotherapy administered?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.33] Radiation Oncology Consultation (05/02/2025): Conclusion:\n",
      "Mr. Henderson expresses gratitude for the thorough explanation. He will consult with Dr. Turner (urology) again before making a final choice. He acknowledges that either surgery or radiation can be curative, and his decision will revolve around which side effect profile he finds more acceptable.\n",
      "\n",
      "2. [0.27] Operative Report - Robotic-Assisted Radical Prostatectomy (05/15/2025): Conclusion:\n",
      "The robotic-assisted radical prostatectomy was completed successfully with partial nerve-sparing on the right side. Mr. Henderson tolerated the procedure well and will be closely observed during the immediate postoperative period. The final pathology report will guide any need for additional therapies such as radiation or hormonal treatment.\n",
      "\n",
      "3. [0.25] Radiation Oncology Consultation (05/02/2025): Plan:\n",
      "- If Mr. Henderson opts for radiation, a CT simulation and MRI fusion would be the next step to precisely map the prostate and adjacent structures.\n",
      "- He is encouraged to weigh the benefits and drawbacks of surgery versus radiation. Both have high cure rates in localized intermediate-risk prostate cancer, though the side effect profiles differ.\n",
      "- Dr. Zhao advises an informed decision after considering quality of life, personal preference, and risk tolerance.\n",
      "\n",
      "\n",
      "Query 3: What follow-up imaging or lab tests were planned to monitor for recurrence?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.45] Urology Follow-up - Discussion of Biopsy Results (04/06/2025): Plan:\n",
      "- Order a prostate MRI and bone scan.\n",
      "- Schedule a follow-up appointment in two weeks to review imaging results and finalize treatment decisions.\n",
      "- Provide patient education materials on surgical and radiotherapy options.\n",
      "\n",
      "2. [0.44] MRI and Bone Scan Results - Staging Evaluation (04/20/2025): Assessment:\n",
      "Based on these imaging findings, Mr. Henderson’s disease is likely clinically staged as T2 N0 M0, which correlates with a stage consistent with organ-confined or at least regionally limited prostate cancer. This staging suggests he is a good candidate for definitive local therapy, such as surgery or radiation.\n",
      "\n",
      "Plan for Treatment:\n",
      "Dr. Turner reaffirms two primary curative approaches:\n",
      "- **Radical Prostatectomy** (Open or Robotic-Assisted): Typically recommended for men with a life expectancy beyond 10 years and localized disease. This could be combined with pelvic lymph node dissection, given his intermediate risk. Potential side effects discussed again include erectile dysfunction, incontinence, and typical surgical risks.\n",
      "- **Radiation Therapy**: External beam radiation therapy over several weeks or brachytherapy. May be combined with short-term androgen deprivation therapy (ADT) if considered necessary for intermediate-risk disease. Side effects can include urinary frequency, dysuria, and bowel-related issues like proctitis.\n",
      "\n",
      "Patient Discussion:\n",
      "Mr. Henderson states that he wants to be aggressive in treating the cancer and is inclined towards surgery. He has concerns about urinary incontinence but acknowledges that modern techniques may help preserve function. Dr. Turner suggests that he also speak with a radiation oncologist to fully understand all options. They review basic guidelines indicating that Gleason 7 disease typically warrants definitive therapy unless significant comorbidities preclude aggressive management.\n",
      "\n",
      "Next Steps:\n",
      "- Refer to a radiation oncology consult if the patient desires a second opinion.\n",
      "- If Mr. Henderson proceeds with surgery, schedule preoperative labs, EKG, and anesthesia consultation.\n",
      "- Begin pelvic floor exercises preoperatively to help with post-surgery continence.\n",
      "\n",
      "3. [0.42] Radiation Oncology Consultation (05/02/2025): Conclusion:\n",
      "Mr. Henderson expresses gratitude for the thorough explanation. He will consult with Dr. Turner (urology) again before making a final choice. He acknowledges that either surgery or radiation can be curative, and his decision will revolve around which side effect profile he finds more acceptable.\n",
      "\n",
      "\n",
      "Query 4: Did the patient undergo surgery?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.46] Operative Report - Robotic-Assisted Radical Prostatectomy (05/15/2025): Conclusion:\n",
      "The robotic-assisted radical prostatectomy was completed successfully with partial nerve-sparing on the right side. Mr. Henderson tolerated the procedure well and will be closely observed during the immediate postoperative period. The final pathology report will guide any need for additional therapies such as radiation or hormonal treatment.\n",
      "\n",
      "2. [0.35] Radiation Oncology Consultation (05/02/2025): Conclusion:\n",
      "Mr. Henderson expresses gratitude for the thorough explanation. He will consult with Dr. Turner (urology) again before making a final choice. He acknowledges that either surgery or radiation can be curative, and his decision will revolve around which side effect profile he finds more acceptable.\n",
      "\n",
      "3. [0.33] Urology Follow-up - Discussion of Biopsy Results (04/06/2025): Plan:\n",
      "- Order a prostate MRI and bone scan.\n",
      "- Schedule a follow-up appointment in two weeks to review imaging results and finalize treatment decisions.\n",
      "- Provide patient education materials on surgical and radiotherapy options.\n",
      "\n",
      "\n",
      "Query 5: Has the patient undergone AC chemotherapy?\n",
      "Most Relevant Treatment Records:\n",
      "1. [0.40] Radiation Oncology Consultation (05/02/2025): Conclusion:\n",
      "Mr. Henderson expresses gratitude for the thorough explanation. He will consult with Dr. Turner (urology) again before making a final choice. He acknowledges that either surgery or radiation can be curative, and his decision will revolve around which side effect profile he finds more acceptable.\n",
      "\n",
      "2. [0.33] MRI and Bone Scan Results - Staging Evaluation (04/20/2025): Assessment:\n",
      "Based on these imaging findings, Mr. Henderson’s disease is likely clinically staged as T2 N0 M0, which correlates with a stage consistent with organ-confined or at least regionally limited prostate cancer. This staging suggests he is a good candidate for definitive local therapy, such as surgery or radiation.\n",
      "\n",
      "Plan for Treatment:\n",
      "Dr. Turner reaffirms two primary curative approaches:\n",
      "- **Radical Prostatectomy** (Open or Robotic-Assisted): Typically recommended for men with a life expectancy beyond 10 years and localized disease. This could be combined with pelvic lymph node dissection, given his intermediate risk. Potential side effects discussed again include erectile dysfunction, incontinence, and typical surgical risks.\n",
      "- **Radiation Therapy**: External beam radiation therapy over several weeks or brachytherapy. May be combined with short-term androgen deprivation therapy (ADT) if considered necessary for intermediate-risk disease. Side effects can include urinary frequency, dysuria, and bowel-related issues like proctitis.\n",
      "\n",
      "Patient Discussion:\n",
      "Mr. Henderson states that he wants to be aggressive in treating the cancer and is inclined towards surgery. He has concerns about urinary incontinence but acknowledges that modern techniques may help preserve function. Dr. Turner suggests that he also speak with a radiation oncologist to fully understand all options. They review basic guidelines indicating that Gleason 7 disease typically warrants definitive therapy unless significant comorbidities preclude aggressive management.\n",
      "\n",
      "Next Steps:\n",
      "- Refer to a radiation oncology consult if the patient desires a second opinion.\n",
      "- If Mr. Henderson proceeds with surgery, schedule preoperative labs, EKG, and anesthesia consultation.\n",
      "- Begin pelvic floor exercises preoperatively to help with post-surgery continence.\n",
      "\n",
      "3. [0.32] Operative Report - Robotic-Assisted Radical Prostatectomy (05/15/2025): Conclusion:\n",
      "The robotic-assisted radical prostatectomy was completed successfully with partial nerve-sparing on the right side. Mr. Henderson tolerated the procedure well and will be closely observed during the immediate postoperative period. The final pathology report will guide any need for additional therapies such as radiation or hormonal treatment.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# List of dataset files\n",
    "dataset_files = ['1.json','2.json','3.json']\n",
    "\n",
    "# List of queries\n",
    "queries = [\n",
    "    \"What were the recommended treatment options based on the patient’s cancer stage and pathology?\",\n",
    "    \"Was chemotherapy administered?\",\n",
    "    \"What follow-up imaging or lab tests were planned to monitor for recurrence?\",\n",
    "    \"Did the patient undergo surgery?\",\n",
    "    \"Has the patient undergone AC chemotherapy?\"\n",
    "]\n",
    "\n",
    "# Store results for plotting\n",
    "query_results = {query: {file: [] for file in dataset_files} for query in queries}\n",
    "\n",
    "# Process each dataset separately\n",
    "for file in dataset_files:\n",
    "    print(f\"\\nProcessing Dataset: {file}\\n\" + \"-\"*50)  # Print dataset file name and separator\n",
    "    \n",
    "    # Load the dataset from the JSON file\n",
    "    with open(file, encoding=\"utf-8\") as f:\n",
    "        patient_data = json.load(f)  # Load patient data from the JSON file\n",
    "\n",
    "    # Create an instance of the EHR retrieval system with the patient data\n",
    "    ehr_system = EHRRetrievalSystem(patient_data)\n",
    "    \n",
    "    # Preprocess the data (clean text, extract relevant treatment sections, etc.)\n",
    "    ehr_system.preprocess()\n",
    "\n",
    "    # Iterate over each query\n",
    "    for query_num, query in enumerate(queries, 1):\n",
    "        results = ehr_system.retrieve(query)  # Retrieve most relevant treatment records for the current query\n",
    "        \n",
    "        # Store the top similarity score for the query and dataset\n",
    "        if results:\n",
    "            top_score = results[0][1]  # Get the score of the most relevant chunk\n",
    "            query_results[query][file].append(top_score)\n",
    "        else:\n",
    "            query_results[query][file].append(0)  # In case no results were found\n",
    "        \n",
    "        # Print query and results\n",
    "        print(f\"\\nQuery {query_num}: {query}\")\n",
    "        print(\"Most Relevant Treatment Records:\")\n",
    "        \n",
    "        # Sort the results by score in descending order and print the top results\n",
    "        for i, (chunk, score) in enumerate(sorted(results, key=lambda x: -x[1]), 1):\n",
    "            print(f\"{i}. [{score:.2f}] {chunk}\\n\")  # Print the chunk and its similarity score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "939cddeb-b560-424e-b2ce-ba5898feb478",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Prepare data for plotting (scores across queries for each dataset)\n",
    "for file in dataset_files:\n",
    "    scores = [query_results[query][file][0] for query in queries]  # Get top score for each query\n",
    "    plt.plot([f'Query {i+1}' for i in range(len(queries))], scores, marker='o', label=f'Dataset {file}')\n",
    "\n",
    "# Add labels and title\n",
    "plt.title('Score vs Query for Different Datasets')\n",
    "plt.xlabel('Query')\n",
    "plt.ylabel('Top Similarity Score')\n",
    "plt.xticks(rotation=45, ha='right')  # Rotate query labels for better readability\n",
    "plt.ylim(0, 1)  # Assuming similarity scores are between 0 and 1\n",
    "plt.legend(title=\"Datasets\")\n",
    "plt.tight_layout()  # Adjust layout for better spacing\n",
    "\n",
    "# Display the graph\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "67c9caac-b362-446a-b5f8-65560408d874",
   "metadata": {},
   "source": [
    "### Explanation for Plotting the Graph:\n",
    "\n",
    "This plot shows how well the retrieval system performs across different queries and datasets. Here's a simplified breakdown:\n",
    "\n",
    "1. **Data Representation**:\n",
    "   - The plot compares the top similarity scores for each query across multiple datasets.\n",
    "   - A higher score means the dataset's treatment record is more relevant to the query.\n",
    "\n",
    "2. **Structure of the Plot**:\n",
    "   - The x-axis represents the queries (labeled as `Query 1`, `Query 2`, etc.) for simplicity.\n",
    "   - The y-axis shows the similarity score, which ranges from 0 (no relevance) to 1 (perfect relevance).\n",
    "\n",
    "3. **Dataset Comparison**:\n",
    "   - Each dataset is represented by a line, and its top similarity score for each query is plotted.\n",
    "   - The legend shows which line corresponds to each dataset.\n",
    "\n",
    "4. **Plot Styling**:\n",
    "   - Query labels on the x-axis are rotated for better readability.\n",
    "   - The y-axis is set from 0 to 1, assuming scores fall within this range.\n",
    "   - A tight layout ensures the plot fits well on the screen.\n",
    "\n",
    "5. **Insights**:\n",
    "   - This graph allows easy comparison of how well each dataset matches the queries. If a dataset consistently scores higher, it’s more relevant to the queries.\n",
    "   - The plot helps assess how well the system works with each dataset.\n",
    "\n",
    "6. **Model Performance**:\n",
    "   - The graph also shows how our model performed across different datasets for various queries, helping to evaluate its overall effectiveness.\n",
    "\n",
    "In short, this graph provides a visual way to understand how different datasets perform in response to specific queries.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c1329692-7d9d-4421-9e2d-022f430eab04",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
